REG - Biofrontera AG - Ameluz distribution for Spanish market <Origin Href="QuoteRef">B8FGn.DE</Origin>

Biofrontera AGAnnouncement

10/11/2014 09:39

RNS Number : 4469W
Biofrontera AG
07 November 2014
07 November 2014
Biofrontera AG
("Biofrontera" or the "Company")
Biofrontera to take over the sales and marketing of Ameluz in Spain from Allergan 
 Change will be effected in March 2015
 Key Account Manager for dermatology will transfer to Biofrontera
 No financial obligations between the companies
 New structure captures the full margin for Biofrontera
Leverkusen, 07 November 2014 - Biofrontera AG (FSE: B8F), the biopharmaceutical company focusing on skin cancer, announced today that it has agreed with Allergan SA to take over distribution (marketing and sales) activities for Ameluz and BF-RhodoLED in Spain.
Allergan is currently realigning its business strategy with a focus on three main business areas, Ophthalmology, Neuroscienceand Medical Aesthetics. Allergan has successfully launched Ameluz in the Spanish market after having achieved all necessary local regulatory prerequisites, such as the determination of pricing and full reimbursement. Allergan has been very successful in getting a large number of Spanish hospitals to started using Ameluz for photodynamic therapy. Allergan will now work closely with Biofrontera to ensure a smooth transition of marketing and sales activities in Spain. 
In connection with the transfer, Biofrontera is pleased to announce that Allergan's Key Account Manager for Dermatology will continue working with Ameluz and has therefore agreed to transfer to Biofrontera, acting as the nucleus of Biofrontera's future marketing and sales organization in Spain.
The new distribution arrangement will become effective in March 2015, allowing Biofrontera sufficient time to register Biofrontera Pharma GmbH as the Spanish distributor of Ameluz and prepare marketing and sales activities. The agreement does not create any financial obligation between the parties. This transfer will result in Biofrontera capturing the full margin as a direct vendor, which will significantly increase profitability forBiofrontera in respect of sales in Spain. Product revenues are expected to balance Biofrontera's further investment into marketing and sales in Spain within 12 months. Biofrontera appreciates all of Allergan's efforts in successfully launching Ameluz in Spain, one of the most important European markets for photodynamic therapy.
ends.
For enquiries, please contact: 
Biofrontera AG

Prof. Hermann Lbbert, Chief Executive Officer
Thomas Schaffer , Chief Financial Officer
Tel:+ 49 (0) 214 87632 0 


Nomad and Broker: Shore Capital
Tel: +44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs



Investor Relations: Seton Services
Tel: +44(0) 20 7603 6797
Toni Vallen



Financial PR: Gable Communications
John Bick
Tel: +44(0) 20 7193 7463
Tel: +44 (0)7872 061007

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCQKODDFBDKKDK